Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-17

I believe they are awaiting Japanese approval. Apparently the largest dementia percentages globally (not nice static to have. Once FDA approval and Japanse approval obtained it should just be a numbers game on the care home front. If they achieve 60% in just these two markets they will be a cash machine. This is not going to happen over night, but if they achieve the approvals serious interest will come. I wouldn't be surprised if they have a take over offer before the end of year should they gain approvals.
Should the Welsh and Scottish hospital trials also prove successful maybe they will be on the radar of INEOS and Sir Jim Radcliff as well. Lots of upside at the moment. The down side is not too great tbh just going to take time for the training to catch up to the sales side. This will happen though as they expand the training side.